Program Description Triple-negative breast cancer (TNBC) is aggressive and has the highest rate of metastatic disease and lowest survival rate compared with other breast cancer subtypes. Treatment is challenging due...
Read More
Portfolio
CE Manuscripts
March 12, 2021 Douglas S. Burgoyne, PharmD, FAMCP Supplements and Featured Publications, Improving Economic and Quality of Life Burden in Pulmonary Arterial Hypertension: A Review of Clinical Data and Strategies to...
Read More
White Papers
September 14, 2021 Supplements and Featured Publications, Strategies for Effective Cardiovascular Risk Management Through Lipid Management: A Transitional Approach From Hospital to Home, This publication was sponsored and written in partnership…
May 27, 2021 Supplements and Featured Publications, Considerations for Future Management of Autoimmune Therapies, This publication was written in partnership with and paid for by Pfizer Inc. The landscape for autoimmune…
Publications
Babette S Edgar, PharmD, MBA, FAMCP; Adam S Cheifetz, MD; Simon M Helfgott, MD; Gideon P Smith, MD, MPH, PhD; Tina Bandekar, RPh; Adam Hoye-Simek, PharmD; YuQian Liu, PharmD, RPh;…
JHOP – August 2020 Vol 10, No 4 – HOPA Corner By Marielle Fares, PharmD, BCGP, MBA; and the Hematology/Oncology Pharmacy Association (HOPA) Standards Committee: Bernadette B. Heron, PharmD, BCOP, Chair; Sol…
Feature Articles
Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors. Oncoloytic viruses (OVs) are an emerging class of cancer therapeutics that may…
Research on combination therapies involving human papillomavirus-targeted vaccines and immunotherapies continues to expand in phase 2 and 3 trials in patients with head and neck squamous cell carcinoma. Robert L….
